Excerpts

A p -value of <0.05 was regarded statistically significant, while p -values of <0.01 were considered highly significant. 3.

Patients with a TBRmax higher than 4.5 showed a significant worse prognosis than those with TBRmax ≤ 4.5 with a negative trend from 1 to 3 year survival.

Regarding PFS, a favorable trend was recorded in cases of younger patients with methylated MGMT and without residual tumor volume but without statistically significant values.

The statin groups showed a trend toward reduced MI events and death, but did not reach significance.

Use of beta blockers and higher blood pressure seemed to be protective against AKI, albeit reaching only borderline significance ( Table 4 ). 4.

The prevalence of psoriasis has been showing an increasing trend in certain countries [ 2 , 4 , 5 ].

Introduction An increasing trend of prevalence of autoimmune hepatitis (AIH) was found according to the nationwide epidemiologic survey [ 1 ].

Their work suggests there may be significant nuance in the relationship between AAV vector CpG content, innate immune signaling, and the subsequent induction of anti-capsid T-cell response.

An increasing trend in the ventilatory ratio during MV until approximately 2 weeks was observed in both groups.

We observed a decreasing trend in respiratory static compliance despite the higher PEEP setting after day 5 and a higher ventilatory ratio in patients with prolonged MV than in those with early liberation.

Finally, in a retrospective study that included solid organ transplant patients with type 2 diabetes mellitus (diagnosed pre- or post-transplant) and stage 3–4 of CKD in more than 70% of the patients, dulaglutide compared with liraglutide showed a trend towards improved kidney function over a 24-month follow-up period [ 96 ].

With moderate confidence, HCQ showed a trend towards reducing the need for mechanical ventilation at 30 days by 7%, with low confidence HCQ showed a trend towards speeding hospital discharge by 3%, and with very low confidence HCQ showed a trend towards improving clinical recovery by 26%.

A highly significant difference was seen between patients and controls in the education level.

Results with significance levels p < 0.10 were considered as marginally significant.

What may be significant, especially in the context of asthmatic patients, is that the one-way valve prevents the inhalation of cold air by the patient through the condenser and then prevents unintentional cold air challenge [ 9 ].

However, a statistical trend was reported with respect to the higher values of the knee flexion angle and lower values on the VAS scoring scale in patients who received KT.

As expected, the effect of MD alone on PD showed a highly significant correlation at every location.

However, the difference in the percentage of CD3 + CD56 + CD44 + CD161 + (NKT) cells after 48 h of culturing of PBMC fell short of significance, although with a trend to increase in RPL patients [ 44 , 48 , 49 ].

In three studies, investigating a similar “disstress management” over a one year period and following patients for an additional 5 years, there was a homogeneous trend towards reduction in cardiovascular morbidity (non-fatal MI, unstable angina, stroke, TIA, PCI, CABG, and peripheral revascularisation) that just failed to be significant (RR 0.74; 95% CI (0.51–1.07) [ 212 ].

There was a positive trend towards reduction in depressive symptoms for “distress management” and “lifestyle changes”.

As shown in Table 3 , there was a marginally significant relationship between the cumulative number of inflammatory conditions between the CS and AD groups.

A p -value < 0.05 was considered to be statistically significant and p -value < 0.01 was considered to be statistically highly significant. 3.

As far as the subgroup of naive patients with HCC is concerned, the overall proportion of patients deemed eligible for atezolizumab plus bevacizumab was 7.1%, ranging from 5.3% to 5.4% (2008–2014) up to 10.7% (2019), with a median eligibility rate for the novel therapy in this group of patients of 7.5%, and with an increasing trend observed in the most recent years ( Figure 3 A).

With regard to patients with HCC recurrence after surgery or locoregional treatment, after excluding those not eligible for the treatment with atezolizumab plus bevacizumab as per the study inclusion and exclusion criteria, the overall eligibility rate to this ICI-based therapy was 36.3%, with a median eligibility rate across the whole period of 36.5% (range, 28.9% to 44.4%), with a decreasing trend observed in the most recent years ( Figure 3 B).

The presence of both COX-negative and SDH-positive ragged red/blue fibers ( p = 0.037) showed a trend towards significance in the patients harboring mtDNA mutations.